Vietnamese-made COVID-19 vaccine Nanocovax is in the thirrd phase of clinical trials |
Recently, South Korean pharmaceutical company HLB was said to have signed an MoU with Nanogen Pharmaceutical Biotechnology JSC to acquire the rights to supply the Vietnamese COVID-19 vaccine Nanocovax across the globe, except for Vietnam and India.
The two sides agreed with the transfer of technology for the Korean firm to produce and sell the Vietnamese partner's vaccine, as well as to carry out marketing campaigns globally. They plan to finish negotiations once scientists finish reviewing the clinical data on Nanocovax within the next three months.
Nanocovax is Vietnam's domestically developed coronavirus vaccine candidate. The vaccine is in the phase of clinical trials.
In early August, India’s Vekaria Pharmaceutical Group inked a deal with Nanogen to supply Nanocovax to the world's second-most populous country.
The deals are expected to help the Vietnamese-made COVID-19 vaccine soon join global supply chain, easing the global shortfall of COVID-19 vaccines.
Nanogen ties up with Vekaria Healthcare LLP to produce Nanocovax vaccine |
Volunteers receive second shots of Nanocovax vaccine |
Volunteers get 2nd shot of 25mcg dose of Nanocovax |
What the stars mean:
★ Poor ★ ★ Promising ★★★ Good ★★★★ Very good ★★★★★ Exceptional